Company and market role
TMI Robotics Co., Ltd was founded in 2015 and has its documented headquarters in Shanghai, China. The company operates in surgical and medical robotics. Its portfolio addresses Surgery, Diagnostics, Healthcare and Rehabilitation, giving it a defined role in the robotics value chain rather than covering the market as a whole.
The source dataset lists the following specialist subsegments: Chemistry-Positive Disinfection, Commercial Cleaning, Disinfection & Sterilization, Surgical Systems. For classification in the Alpha Bionic Robotics Atlas, the decisive question is whether the company supplies proprietary hardware, software, components or integration into an operational solution. This distinction prevents manufacturers, integrators and platform providers from being treated as equivalent.
Products and technical focus
The publicly named portfolio includes Smart Disinfection Robot, Ward Service Robot, Flexible Hospital Logistics Robot, Medical Waste Transport Robot, High-Value Consumables Management Robot, Special Drug Control Robot, Post-Surgery Instrument Recovery Robot and Medical AI Assistant (Admission Robot). Product names indicate the breadth of the offer but are not a technical acceptance test. Prospective buyers should request the current datasheet, supported interfaces, safety functions, software version and deliverable configuration for each model directly from the supplier.
The structured source dataset includes these specification notes: Smart Disinfection Robot: Ultra-dry-fog H2O2 <3um (patent 201821365437.5); 9x 25W ozone-free 253.7nm UV tubes, >90uW/cm2 @1m; plasma module; real-time H2O2 concentration + PM2.5/temp/humidity sensors; pedestrian detection auto-stops UV; RealSense anti-fall; 7x24h autonomous, auto-recharge. Gen2: 4x irradiation, 5x liquid capacity, 2x atomization, 5x efficiency, 2x battery vs Gen1.; Ward Service Robot: Vitals: body temp / blood pressure / heart rate; thyroid iodine-uptake radiation measurement; microphone array voice interaction; face recognition; electromagnetically-locked medicine box; multi-sensor obstacle avoidance.; Flexible Hospital Logistics Robot: Payload chassis tiers 100 / 200 / 500 kg; cm-level real-time positioning, high-precision mapping, rapid obstacle avoidance, autonomous elevator and door operation, high-power auto-charging; central multi-robot dispatch with traffic control and traceability.. They provide initial orientation and should be checked against current product documentation before any purchase or investment decision.
Applications and procurement questions
The Atlas assigns TMI Robotics Co., Ltd to the application areas Surgery, Diagnostics, Healthcare and Rehabilitation. Commercial viability depends on more than the robot hardware: process design, peripherals, training, local integration and technical support often account for the larger share of project risk.
A supplier review should clarify performance limits, environmental robustness, safety, integration effort, maintenance and local support. Reference customers, delivery times, warranty terms, cybersecurity, data flows and service coverage in the intended country of use should also be documented. This separates a product announcement from an operable end-to-end system.
Editorial assessment
The combination of a longer market presence and a named product portfolio suggests more than a demonstration project. The Atlas therefore assesses traceability of the offer and suitability for a specific use case rather than brand awareness. TMI Robotics Co., Ltd is most relevant when its named products and capabilities match the buyer’s actual process problem.
This profile is a structured initial assessment. It consolidates company data, product names, segment classification and key due-diligence questions without repeating unverified claims about sales, performance or autonomy. New primary sources, certifications or credible reference projects can be added during the next editorial review.
Assessment of development status
Structured initial editorial assessment based on the public Asia Bits product dataset and the company’s official website, reviewed on 7 August 2026. The maturity rating “Established provider” describes the documented market offering; it is not, by itself, independent proof of shipment volumes, shift operation or economic viability.